Aprea Therapeutics, Inc.
APREHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, Aprea Therapeutics, Inc. (APRE) is listed under Biotechnology. The company carries a $8.1M market cap, placing it firmly in the micro-cap category. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Market Cap
$8.1M
Beta
1.56
P/E (TTM)
—
P/E (Fwd)
-0.83
EPS (TTM)
$-1.43
EPS (Fwd)
$-0.79
ROE
-40.4%
ROA
-23.2%
Cash
$46.5M
Total Debt
$0
Free CF
-$5.6M
52W Change
-68.7%
Annual Financials
Cash vs Debt
Where APRE stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, APRE finished 12.20% below its 150-day moving average ($0.82) and 25.00% below its 200-day moving average ($0.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APRE overbought or oversold?
At the July 14, 2026 close, APRE's RSI(14) was 37.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aprea Therapeutics, Inc. reports $46.5M in cash and $0 in total debt. Free cash flow is running at -$5.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -40.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, APRE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aprea Therapeutics, Inc. and its sector.